ES3056923T3 - Benzimidazole dimers as modulators of sting - Google Patents

Benzimidazole dimers as modulators of sting

Info

Publication number
ES3056923T3
ES3056923T3 ES20901732T ES20901732T ES3056923T3 ES 3056923 T3 ES3056923 T3 ES 3056923T3 ES 20901732 T ES20901732 T ES 20901732T ES 20901732 T ES20901732 T ES 20901732T ES 3056923 T3 ES3056923 T3 ES 3056923T3
Authority
ES
Spain
Prior art keywords
benzo
ethane
methoxy
bis
diyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20901732T
Other languages
English (en)
Spanish (es)
Inventor
Benjamin Joseph Morrow
Jonathan Grant Hubert
Paul Anthony Stupple
Michelle Ang Camerino
Matthew Lloyd Dennis
Anthony Nicholas Cuzzupe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTXT Pty Ltd
Original Assignee
CTXT Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1918761.6A external-priority patent/GB201918761D0/en
Priority claimed from GBGB2009944.6A external-priority patent/GB202009944D0/en
Application filed by CTXT Pty Ltd filed Critical CTXT Pty Ltd
Application granted granted Critical
Publication of ES3056923T3 publication Critical patent/ES3056923T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES20901732T 2019-12-18 2020-12-18 Benzimidazole dimers as modulators of sting Active ES3056923T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1918761.6A GB201918761D0 (en) 2019-12-18 2019-12-18 Compounds
GBGB2009944.6A GB202009944D0 (en) 2020-06-30 2020-06-30 Compounds
PCT/AU2020/051394 WO2021119753A1 (en) 2019-12-18 2020-12-18 Compounds

Publications (1)

Publication Number Publication Date
ES3056923T3 true ES3056923T3 (en) 2026-02-25

Family

ID=76476453

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20901732T Active ES3056923T3 (en) 2019-12-18 2020-12-18 Benzimidazole dimers as modulators of sting

Country Status (8)

Country Link
US (1) US12415785B2 (enExample)
EP (1) EP4077318B1 (enExample)
JP (2) JP7662644B2 (enExample)
CN (1) CN114981265B (enExample)
AU (1) AU2020409429A1 (enExample)
CA (1) CA3164751A1 (enExample)
ES (1) ES3056923T3 (enExample)
WO (1) WO2021119753A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022266711A1 (en) * 2021-06-23 2022-12-29 Aculeus Therapeutics Pty Ltd Substituted amidobenzimidazole dimers as sting modulators
CN113603661B (zh) * 2021-08-11 2024-04-09 沈阳药科大学 (s)-5-氟-3-甲基异苯并呋喃-3-酮的合成方法
CN114349662A (zh) * 2022-01-20 2022-04-15 杭州裕普润生物科技有限公司 一种溴化苄的制备方法
CN114671747B (zh) * 2022-04-08 2024-10-29 浙江永太科技股份有限公司 一种4-氯-2-氟苯甲醛的合成方法
EP4615962A1 (en) * 2022-11-09 2025-09-17 Kathleen E. Clarence-Smith Pharmaceutical combination for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma
WO2024174863A1 (zh) * 2023-02-22 2024-08-29 深圳众格生物科技有限公司 Sting激动剂及其制备方法和医药用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5414010A (en) * 1994-05-10 1995-05-09 Warner-Lambert Company Dimeric benzimidazoles as central nervous system agents
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
EP1065213A3 (en) 1999-07-02 2003-11-05 Japan Tobacco Inc. HCV polymerase suitable for crystal structure analysis and method for using the enzyme
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
EP1162196A4 (en) 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
WO2001090129A2 (en) 2000-05-19 2001-11-29 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU8100101A (en) 2000-08-04 2002-02-18 Corixa Corp New immunoeffector compounds
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
IL157940A0 (en) 2001-03-19 2004-03-28 Ono Pharmaceutical Co Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
WO2003085375A2 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
NZ536746A (en) 2002-06-13 2007-02-23 Crucell Holland Bv An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
BR0315417A (pt) 2002-10-24 2005-08-16 Glaxo Group Ltd Derivados 1-acil-pirrolidina para o tratamento de infecções virais
US7271172B2 (en) 2002-12-13 2007-09-18 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as CCR5 antagonists
JP2006512339A (ja) 2002-12-13 2006-04-13 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのインダン化合物
AU2003300911A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
AU2003296993A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
ES2311755T3 (es) 2002-12-13 2009-02-16 Smithkline Beecham Corporation Compuestos de ciclohexilo como antagonistas de ccrs.
RU2005118407A (ru) 2002-12-13 2006-03-10 СмитКлайн Бичем Корпорейшн (US) Производные пиперидина в качестве антагонистов ccr5
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
UY28758A1 (es) 2004-02-20 2005-09-30 Boehringer Ingelheim Int Inhibidores de polimerasa viral
JP4931798B2 (ja) 2004-03-15 2012-05-16 ケイ．アール． カラオリス，デイヴィッド 免疫、炎症または神経保護応答のための方法
WO2005105761A1 (en) 2004-04-28 2005-11-10 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
ES2361845T3 (es) 2004-08-18 2011-06-22 Pfizer, Inc. Inhibidores de arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones y tratamientos que utilizan los mismos.
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
SG159561A1 (en) 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
PL2559690T3 (pl) 2005-05-10 2016-09-30 Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
KR101577843B1 (ko) 2007-12-14 2015-12-16 브리스톨-마이어스 스큅 컴퍼니 인간 ｏｘ４０ 수용체에 대한 결합 분자
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
NO2504364T3 (enExample) 2009-11-24 2018-01-06
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
WO2012027328A2 (en) 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
MX373443B (es) 2011-03-31 2020-05-20 Inst Nat Sante Rech Med Anticuerpos dirigidos contra icos y usos de los mismos.
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
KR101685262B1 (ko) 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
JP2015516989A (ja) 2012-04-30 2015-06-18 バーバー, グレン, エヌ.BARBER, Glen, N. 免疫反応の変調
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
US10414747B2 (en) 2016-10-04 2019-09-17 Merck Sharp & Dohme Corp. Benzo[b]thiophene compounds as sting agonists
CA3067257A1 (en) 2017-06-22 2018-12-27 Curadev Pharma Limited Small molecule modulators of human sting
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
GB2563642A (en) 2017-06-22 2018-12-26 Curadev Pharma Ltd Small molecule modulators of human STING
JP2020524717A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
CN110016025B (zh) * 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
CA3091670C (en) 2018-02-21 2023-02-28 The Scripps Research Institute 6(1h-imidazolyl)pyridazine compounds as agonists of stimulator of interferon genes sting
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
EP3774764A1 (en) 2018-04-03 2021-02-17 Merck Sharp&Dohme Corp. Benzothiophenes and related compounds as sting agonists
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
ES2929415T3 (es) * 2018-05-25 2022-11-29 Incyte Corp Compuestos heterocíclicos tricíclicos como activadores de STING

Also Published As

Publication number Publication date
CN114981265A (zh) 2022-08-30
EP4077318A4 (en) 2023-11-22
CN114981265B (zh) 2025-01-03
EP4077318A1 (en) 2022-10-26
CA3164751A1 (en) 2021-06-24
AU2020409429A1 (en) 2022-06-16
JP7662644B2 (ja) 2025-04-15
US12415785B2 (en) 2025-09-16
JP2025061311A (ja) 2025-04-10
JP2023506899A (ja) 2023-02-20
US20230062932A1 (en) 2023-03-02
EP4077318B1 (en) 2025-10-15
WO2021119753A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
ES2971809T3 (es) Tiofenos condensados sustituidos como moduladores de STING
JP7662644B2 (ja) 化合物
JP7607627B2 (ja) Ｓｔｉｎｇのモジュレーションのためのベンゾチオフェン、チエノピリジンおよびチエノピリミジン誘導体
WO2022266711A1 (en) Substituted amidobenzimidazole dimers as sting modulators
JP7607626B2 (ja) Ｓｔｉｎｇのモジュレーションのためのベンゾチオフェン、チエノピリジンおよびチエノピリミジン誘導体
AU2023407213A1 (en) Benzimidazole derivatives for the modulation of sting
US20260132112A1 (en) Compounds
HK40082951A (en) Benzimidazole dimers as modulators of sting
HK40082951B (en) Benzimidazole dimers as modulators of sting